Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO) in a note issued to investors on Friday. The brokerage set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Stock Performance

Shares of NYSE:CO opened at $1.09 on Friday. The firm has a 50 day simple moving average of $0.96 and a 200 day simple moving average of $1.09. Global Cord Blood has a 52 week low of $2.03 and a 52 week high of $5.50. The company has a market cap of $132.49 million, a PE ratio of 1.70 and a beta of 0.16.

Global Cord Blood Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.